



A natural solution to address weight loss

TECHNOLOGY

Leveraging the foaming capacity of food ingredients

The technology is composed of two sachets containing:


A gel including natural active ingredients that can expand into a foam when it comes into contact with acid.

An acidic powder to be diluted, which will enable the full expansion of the gel.

Both sachets have to be taken twice a day, before main meals.



Jellynov's technology expands to create an **early fullness**. Its impact is **transitory and leaves the body naturally** with the food.



Early sensation
of fullness



Resulting in a lower
daily caloric intake




Subsequent
weight loss

TECHNOLOGY

How it works

Jellynov's ingredients generate CO₂ in contact of the stomach acidity, forming a voluminous, rigid and stable foam that will increase perception of fullness and thus reduce food intake during meals.





Pre-clinical studies

ANIMAL STUDIES - Overview

Demonstrated swelling, elimination & appetite reduction



N=4

2019



N=8

2021



N=1

2021

Demonstration of tolerance & early efficiency:

- No significant change in stools / biological values
- food intake reduction over 12 days

Demonstration by MRI of:

- Gastric swelling in few min
- Natural elimination in 4h

Demonstration by radiography of:

- Swelling & natural elimination
- Resistance to gastric emptying compare to hydro-swelling appetite suppressant





ANIMAL STUDIES – Market

Despite above positive results, all numerous approaches made to pet food manufacturers have resulted in refusals to cooperate

HUMAN MRI STUDY - N = 10

In-human swelling and safety confirmed (Spring & Autumn 2024)


➔ **But: in vivo volumes much smaller than in vitro one's**





Intellectual Property

JELLYNOV IS PROTECTED BY SEVERAL PATENTS



JELLYNOV have applied for several patents worldwide (mainly in Europe and the USA).


→ It should be noted that some patents have been recently contested regarding their patentability.



Regulatory Pathways / main threats & NoGo...

REGULATORY PATHWAY

1 technology, 2 possible routes to market



THREATS / NOGO

- **Stability:**
 - Stabilizing the product over the long term could be a difficult challenge.
- **Taste:**
 - Today the taste is not satisfactory
- **Biocomp:**
 - To be documented carefully
- **Weight loss efficiency:**
 - Pre-clinical trials have shown some effectiveness in appetite reduction, but without a placebo and on a small number of individuals. Will this be confirmed by weight loss?
- **Industrial Scale-up:**
 - TBD. First trials have failed
-
- **MARKET: GLP-1 and its derivatives pose a significant threat due to their efficacy and benefits in numerous comorbidities.**